CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05477563
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:09.332703+00:00
Published At: 2026-03-23T00:00:00+00:00
Record Updated At: 2026-03-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Beta-Thalassemia", "Thalassemia", "Hematologic Diseases", "Genetic Diseases, Inborn", "Hemoglobinopathies", "Sickle Cell Disease", "Sickle Cell Anemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-23"
protocolSection.identificationModule.nctId: "NCT05477563"
protocolSection.identificationModule.officialTitle: "A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent \u03b2-Thalassemia or Severe Sickle Cell Disease"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.